AU2007298539B2 - Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia - Google Patents

Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia Download PDF

Info

Publication number
AU2007298539B2
AU2007298539B2 AU2007298539A AU2007298539A AU2007298539B2 AU 2007298539 B2 AU2007298539 B2 AU 2007298539B2 AU 2007298539 A AU2007298539 A AU 2007298539A AU 2007298539 A AU2007298539 A AU 2007298539A AU 2007298539 B2 AU2007298539 B2 AU 2007298539B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
hydrogen
phenoxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007298539A
Other languages
English (en)
Other versions
AU2007298539A1 (en
Inventor
Swapnil Ramesh Bajare
Nabajyoti Deka
Sivaramakrishnan Hariharan
Rosalind Adaikalasamy Marita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of AU2007298539A1 publication Critical patent/AU2007298539A1/en
Assigned to Piramal Enterprises Limited reassignment Piramal Enterprises Limited Request for Assignment Assignors: PIRAMAL LIFE SCIENCES LIMITED
Application granted granted Critical
Publication of AU2007298539B2 publication Critical patent/AU2007298539B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2007298539A 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia Ceased AU2007298539B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US60/846,194 2006-09-21
US87567206P 2006-12-18 2006-12-18
US60/875,672 2006-12-18
PCT/IB2007/053811 WO2008035305A2 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

Publications (2)

Publication Number Publication Date
AU2007298539A1 AU2007298539A1 (en) 2008-03-27
AU2007298539B2 true AU2007298539B2 (en) 2013-05-02

Family

ID=39048032

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2007298539A Ceased AU2007298539B2 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
AU2007298540A Ceased AU2007298540B2 (en) 2006-09-21 2007-09-20 3 -amino- pyridine derivatives for the treatment of metabolic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2007298540A Ceased AU2007298540B2 (en) 2006-09-21 2007-09-20 3 -amino- pyridine derivatives for the treatment of metabolic disorders

Country Status (19)

Country Link
US (5) US8030324B2 (enExample)
EP (2) EP2094663B1 (enExample)
JP (2) JP5331953B2 (enExample)
KR (2) KR20090075827A (enExample)
AR (2) AR062941A1 (enExample)
AT (1) ATE496890T1 (enExample)
AU (2) AU2007298539B2 (enExample)
BR (2) BRPI0718510A2 (enExample)
CA (2) CA2663901A1 (enExample)
DE (1) DE602007012299D1 (enExample)
DK (1) DK2094663T3 (enExample)
IL (2) IL197695A0 (enExample)
MX (2) MX2009002905A (enExample)
NZ (2) NZ576197A (enExample)
PL (1) PL2094663T3 (enExample)
PT (1) PT2094663E (enExample)
RU (2) RU2448093C2 (enExample)
TW (2) TW200820970A (enExample)
WO (2) WO2008035305A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
PE20160664A1 (es) 2013-06-27 2016-07-09 Pfizer Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
MX2023005371A (es) 2020-11-09 2023-05-22 Eisai R&D Man Co Ltd Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
WO2006037501A1 (en) * 2004-10-04 2006-04-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
NZ515087A (en) * 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HK1052351B (en) * 2000-06-28 2006-11-03 Japan Tobacco Inc. Benzothiazolyl ppar-gamma modulators
CA2526204A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US8188277B2 (en) * 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY
WO2006037501A1 (en) * 2004-10-04 2006-04-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes

Also Published As

Publication number Publication date
WO2008035305A8 (en) 2009-03-12
US20120309786A1 (en) 2012-12-06
DK2094663T3 (da) 2011-04-26
US8030324B2 (en) 2011-10-04
US20100022554A1 (en) 2010-01-28
JP2010504322A (ja) 2010-02-12
JP2010504321A (ja) 2010-02-12
TW200817364A (en) 2008-04-16
BRPI0718510A2 (pt) 2013-11-19
CA2663901A1 (en) 2008-03-27
WO2008035305A2 (en) 2008-03-27
AR062941A1 (es) 2008-12-17
AU2007298539A1 (en) 2008-03-27
MX2009002906A (es) 2009-06-30
AR062940A1 (es) 2008-12-17
IL197695A0 (en) 2009-12-24
MX2009002905A (es) 2009-06-19
EP2094663B1 (en) 2011-01-26
AU2007298540A1 (en) 2008-03-27
US20090247574A1 (en) 2009-10-01
US8269010B2 (en) 2012-09-18
PL2094663T3 (pl) 2011-07-29
KR20090075827A (ko) 2009-07-09
IL197694A0 (en) 2009-12-24
NZ576197A (en) 2011-12-22
KR20090074775A (ko) 2009-07-07
EP2094663A2 (en) 2009-09-02
RU2009114545A (ru) 2010-10-27
CA2663943A1 (en) 2008-03-27
AU2007298540B2 (en) 2013-02-21
EP2094687A1 (en) 2009-09-02
DE602007012299D1 (de) 2011-03-10
JP5331953B2 (ja) 2013-10-30
NZ576196A (en) 2011-12-22
RU2448093C2 (ru) 2012-04-20
WO2008035305A3 (en) 2008-06-12
US20110312970A1 (en) 2011-12-22
BRPI0717106A2 (pt) 2013-10-08
ATE496890T1 (de) 2011-02-15
PT2094663E (pt) 2011-04-19
RU2460729C2 (ru) 2012-09-10
US8349862B2 (en) 2013-01-08
RU2009114544A (ru) 2010-10-27
US20130040988A1 (en) 2013-02-14
WO2008035306A1 (en) 2008-03-27
TW200820970A (en) 2008-05-16

Similar Documents

Publication Publication Date Title
US8349862B2 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
KR20120003941A (ko) 신규 갑상선 호르몬 β 수용체 작동약
EA016415B1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
KR20200051777A (ko) 플루오로페닐 베타-히드록시에틸아민 및 과혈당증의 치료에서의 이의 용도
WO2016108282A1 (ja) Ｕｒａｔ１阻害剤
WO2011130515A1 (en) Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
SK164598A3 (en) 5-phenoxyalkyl-2,4-thiazolidinedione derivative, method for the preparaton thereof, intermediate products for its preparation and pharmaceutical composition containing same
WO2004071509A1 (ja) オリゴデンドロサイト分化促進剤
US20100216823A1 (en) Spirocyclic Derivatives
WO2014180544A1 (en) Hydantoine derivatives as cd38 inhibitors
EP3259256B1 (en) Compounds and methods for inducing browning of white adipose tissue
CN101547902B (zh) 治疗与胰岛素抵抗或高血糖症相关的代谢障碍的吡啶衍生物
CN120865048A (zh) Mas相关g蛋白受体x4调节剂及用途
WO2000044756A1 (en) Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PIRAMAL ENTERPRISES LIMITED

Free format text: FORMER APPLICANT(S): PIRAMAL LIFE SCIENCES LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired